- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists
Patients Taking INVOKANA® 300 mg Were Significantly Less Likely to Discontinue the Medication or Be Prescribed a New Antihyperglycemic Agent
Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Rates of Major Bleeding Across Groups
Filing seeks update to prescribing information to include additional dosage of XARELTO® to reduce risk of recurrent VTE
European Commission Extends Approval for Janssen’s DARZALEX®▼(daratumumab) to Include Multiple Myeloma Patients Who Have Received at Least One Prior Therapy
First-in-class CD38-directed monoclonal antibody now approved for use in combination with two standard of care regimens
Janssen Collaborates with Premier Inc. on Unique Study to Improve Stroke Risk Management among Hospitalized Patients with Atrial Fibrillation
The QUANTUM AF study will evaluate the impact of a hospital quality improvement program on the use of new guidelines to treat patients with atrial fibrillation (AF) at risk for ischemic stroke
Johnson & Johnson Innovation Launches Advancing the Safe Use of Healthcare Products QuickFire Challenge
Challenge awards up to $200,000 to novel solutions that advance safety by informing patients and consumers, simulating surgical procedures or ensuring proper storage and use of prescription, over-the-counter and cosmetic products
Janssen Discontinues Development of Flubendazole Formulation to Treat Onchocerciasis
Research supported Johnson & Johnson’s commitment to the 2012 London Declaration on Neglected Tropical Diseases and yielded important findings